Retractable Q1 2023 sales down 75% to $11.0M; operating loss of $2.7M vs $9.7M profit a year ago

RETRACTABLE TECHNOLOGIES INC

2023-Q1 EPS reported $0.03 revenue$11,001,102

Total net sales $11.0M for Q1 2023, vs $44.7M in Q1 2022; no U.S. government syringe orders.
Operating loss of $2.7M compared to operating income of $9.7M in prior-year period.
Domestic unit sales fell 77.4%; international revenue down 70.3% due to fewer vaccination campaign orders.
Sales & marketing expenses increased ~33% mainly in travel, trade shows, and sales headcount.
Invested ~$9.0M in U.S. government-backed mutual funds; restructured equity securities by ~$6.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.